Congress Trades in Alexion Pharmaceuticals, Inc. (ALXN)
5 members of Congress have disclosed trading ALXN.
Total trades
13
Purchases
6
Sales
7
Members
5
Est. volume
$135,501
Last traded
Jul 9, 2021
5 members of Congress have disclosed trading Alexion Pharmaceuticals, Inc. (ALXN), with 13 transactions in total — 6 purchases and 7 sales worth an estimated $135,501 at range midpoints, leaning toward selling. The most active ALXN trader is Gilbert Cisneros (5 disclosures). The most recent disclosed ALXN trade was on Jul 9, 2021.
Every disclosed ALXN trade
| Disclosed | Politician | Type | Amount | Traded | |
|---|---|---|---|---|---|
| Aug 13, 2021 | James R. Langevin | Sale | $15,001 | Jul 9, 2021 | filing ↗ |
| Aug 11, 2021 | Dean Phillips | Sale | $1,001 - $15,000 | Jul 21, 2021 | filing ↗ |
| Feb 8, 2021 | Dean Phillips | Purchase | $1,001 - $15,000 | Jan 5, 2021 | filing ↗ |
| Aug 19, 2020 | Gilbert Cisneros D | Purchase | $1,001 - $15,000 | Jul 14, 2020 | filing ↗ |
| Aug 19, 2020 | Gilbert Cisneros D | Purchase | $1,001 - $15,000 | Jul 13, 2020 | filing ↗ |
| Apr 15, 2020 | Gilbert Cisneros D | Purchase | $1,001 - $15,000 | Mar 18, 2020 | filing ↗ |
| Mar 10, 2020 | Gilbert Cisneros D | Purchase | $1,001 - $15,000 | Feb 24, 2020 | filing ↗ |
| Mar 6, 2020 | Dean Phillips | Sale | $1,001 - $15,000 | Feb 28, 2020 | filing ↗ |
| Sep 10, 2019 | Gilbert Cisneros D | Purchase | $1,001 - $15,000 | Aug 14, 2019 | filing ↗ |
| Mar 25, 2019 | Nicholas Van Taylor | Sale | $1,001 - $15,000 | Mar 25, 2019 | filing ↗ |
| Jan 6, 2017 | James R. Langevin | Sale | $15,001 - $50,000 | Jan 6, 2017 | filing ↗ |
| Feb 1, 2015 | Thomas MacArthur | Sale | $1,001 - $15,000 | Jan 27, 2015 | filing ↗ |
| Dec 11, 2014 | James R. Langevin | Sale | $1,001 - $15,000 | Dec 8, 2014 | filing ↗ |
Most active ALXN traders in Congress
Gilbert Cisneros
Democrat
5 trades
JR
James R. Langevin
3 trades
DP
Dean Phillips
3 trades
NV
Nicholas Van Taylor
1 trade
TM
Thomas MacArthur
1 trade
Source: US House Clerk Periodic Transaction Reports. Amounts are disclosed as ranges; estimates use range midpoints. Data may be delayed or contain filer errors. Not investment advice.